Research team has described that the ZEB1 and ZEB2 proteins oppositely regulate muscle adaptation to energy needs during fasting.
Read moreResearchers at the University of Barcelona (UB) are taking part in a consortium working on the research and development of a new drug to treat the cognitive and motor decline associated with the disea...
Read moreThe study, published in the journal Pharmacological Research, presents guidelines to enhance the benefits of statins and physical activity, adapting the recommendations to various patient profiles in ...
Read moreUn estudio propone un novedoso enfoque para frenar la degeneración neuromuscular en pacientes con Esclerosis Lateral Amiotrófica (ELA). Esta patología provoca la pérdida de neuronas motoras y la p...
Read moreARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs backed by Columbus Venture Partners, has announced that the ...
Read moreEl Grupo de investigación en etiología y tratamiento de la escoliosis ha anunciado los resultados de un nuevo tratamiento de la escoliosis que garantiza llevar una vida normal a los pacientes para e...
Read moreThe Nucleic Acids Chemistry group, led by Prof. Ramon Eritja’s of the IQAC (CSIC), is participating in a multidisciplinary network for Myotonic Dystrophy Type 1 (DM1) with other 6 research groups...
Read moreLa principal conclusión es que la presencia de variantes patogénicas en el gen SNUPN puede causar un cuadro clínico de distrofia muscular. También han descrito una serie de procesos moleculares qu...
Read moreA research team from the Institut de Recerca Sant Joan de Déu · SJD Barcelona Children’s Hospital is participating in an international clinical trial of a gene therapy for Duchenne muscular dystro...
Read moreThis is the first study to provide scientific evidence for faster and more effective recovery from muscle injuries through intermittent exposure to low oxygen availability (hypoxia) in a low-barometri...
Read moreEl estudio sitúa la alteración de la vía de señalización p66Shc y del proceso de autofagia en las células madre musculares como principales desencadenantes de su envejecimiento celular
Read moreLa FDA ha aprobado Duvyzat (givinostat), un medicamento oral, para el tratamiento de la Distrofia Muscular de Duchenne (DMD) en pacientes de 6 años o más.
Read more